LTC3209302I2 - - Google Patents
Info
- Publication number
- LTC3209302I2 LTC3209302I2 LTPA2023519C LTPA2023519C LTC3209302I2 LT C3209302 I2 LTC3209302 I2 LT C3209302I2 LT PA2023519 C LTPA2023519 C LT PA2023519C LT PA2023519 C LTPA2023519 C LT PA2023519C LT C3209302 I2 LTC3209302 I2 LT C3209302I2
- Authority
- LT
- Lithuania
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066771P | 2014-10-21 | 2014-10-21 | |
| PCT/US2015/056686 WO2016065019A1 (en) | 2014-10-21 | 2015-10-21 | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTPA2023519I1 LTPA2023519I1 (en:Method) | 2023-06-26 |
| LTC3209302I2 true LTC3209302I2 (en:Method) | 2025-10-10 |
Family
ID=54478240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15791424.3T LT3209302T (lt) | 2014-10-21 | 2015-10-21 | Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti |
| LTPA2023519C LTC3209302I2 (en:Method) | 2014-10-21 | 2023-06-08 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15791424.3T LT3209302T (lt) | 2014-10-21 | 2015-10-21 | Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016021034A8 (pt) | 2014-03-13 | 2021-06-29 | Neuroderm Ltd | composição farmacêutica, uso da mesma e kit |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| TWI755257B (zh) * | 2014-10-21 | 2022-02-11 | 美商艾伯維有限公司 | 卡比多巴及左旋多巴之前藥及使用方法 |
| US20190224220A1 (en) * | 2016-04-20 | 2019-07-25 | Abbvie Inc. | Carbidopa and L-Dopa Prodrugs and Methods of Use |
| WO2017223182A1 (en) * | 2016-06-22 | 2017-12-28 | Medchem Partners, Llc. | Nitric oxide donors |
| WO2018154447A1 (en) * | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| MA50800A (fr) | 2017-11-24 | 2020-09-30 | H Lundbeck As | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson |
| CN110294789A (zh) * | 2018-03-21 | 2019-10-01 | 海南大学 | 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用 |
| EP3849533A4 (en) | 2018-09-13 | 2022-06-22 | University of Canberra | Methods of inhibition |
| CA3117983A1 (en) * | 2018-11-15 | 2020-05-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| CN113727979B (zh) | 2019-05-21 | 2024-09-20 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| JP7562562B2 (ja) | 2019-05-21 | 2024-10-07 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| WO2020234275A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| JP7696829B2 (ja) | 2019-05-21 | 2025-06-23 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) * | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4016288A (en) * | 1975-08-13 | 1977-04-05 | Merck & Co., Inc. | Compositions and method of treating hypertension |
| DD230865B1 (de) * | 1982-08-09 | 1987-05-20 | Dresden Arzneimittel | Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| US4508706A (en) * | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| IT1213182B (it) * | 1984-06-25 | 1989-12-14 | Simes | Derivati di composti a struttura catecolamminica. |
| US4616484A (en) | 1984-11-30 | 1986-10-14 | Kysor Industrial Corporation | Vehicle refrigerant heating and cooling system |
| IT1200427B (it) | 1985-03-22 | 1989-01-18 | Afros Spa | Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| DE69016688T2 (de) * | 1989-04-20 | 1995-10-05 | Zambon Spa | Dopamin-Medikament-Vorstufe. |
| GB9102812D0 (en) | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6576766B1 (en) * | 1997-11-12 | 2003-06-10 | Ariad Pharmaceuticals, Inc. | Signal transduction inhibitors, compositions containing them |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| KR20050016449A (ko) * | 2002-05-29 | 2005-02-21 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형 |
| WO2004000863A1 (ja) | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | プロドラッグ、その医薬としての使用、およびその製法 |
| WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| AU2004270174B2 (en) | 2003-08-29 | 2010-05-20 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CA2543227A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Administration of levodopa and carbidopa |
| EP1751087B1 (en) | 2004-06-04 | 2012-06-27 | XenoPort, Inc. | Levodopa derivatives, and compositions and uses thereof |
| NZ552276A (en) | 2004-07-06 | 2011-03-31 | Abbott Lab | Prodrugs of HIV protease inhibitors |
| BRPI0619425A2 (pt) * | 2005-12-05 | 2011-10-04 | Xenoport Inc | mesilato de pró-fármaco de levedopa, composição farmacêutica, método de preparar (2s)-2- amino-3-(3,4-diidróxi fenil) propanoato de mesilato de (2r)-2- fenil carbonilóxi propila e uso do referido composto |
| JP2009543761A (ja) * | 2006-05-31 | 2009-12-10 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | レボドパ／カルビドパの長期間２４時間腸内投与 |
| CA2654557A1 (en) * | 2006-06-16 | 2007-12-21 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and l-dopa |
| CA2673336A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| GB0713189D0 (en) | 2007-07-06 | 2007-08-15 | Proximagen Ltd | Amino acid derivatives |
| PT2252284E (pt) * | 2008-02-06 | 2011-08-23 | Wockhardt Research Center | COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| BRPI1011031B8 (pt) | 2009-05-19 | 2021-05-25 | Neuroderm Ltd | composição líquida farmaceuticamente aceitável e kit |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| EP2515876B1 (en) | 2009-11-09 | 2016-01-06 | XenoPort, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| WO2011109767A2 (en) | 2010-03-04 | 2011-09-09 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
| DK3326615T3 (da) | 2010-11-15 | 2020-03-09 | Neuroderm Ltd | Kontinuerlig indgivelse af l-dopa-, dopa- decarboxylase-inhibitorer, catechol-o-methyltransferaseinhibitorer og sammensætninger til samme |
| DK2647619T3 (en) | 2010-12-02 | 2015-03-02 | Ono Pharmaceutical Co | NEW RELATIONSHIP AND MEDICAL USE THEREOF |
| AU2011341316A1 (en) | 2010-12-10 | 2013-07-04 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US8765189B2 (en) * | 2011-05-13 | 2014-07-01 | Howmedica Osteonic Corp. | Organophosphorous and multivalent metal compound compositions and methods |
| KR20130070371A (ko) * | 2011-12-19 | 2013-06-27 | 울산대학교 산학협력단 | 퇴행성 신경질환 예방 또는 치료용 조성물 |
| PT2968218T (pt) | 2013-03-13 | 2021-09-24 | Neuroderm Ltd | Combinação para tratamento da doença de parkinson |
| CA2917145C (en) | 2013-03-15 | 2023-10-24 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
| TWI755257B (zh) | 2014-10-21 | 2022-02-11 | 美商艾伯維有限公司 | 卡比多巴及左旋多巴之前藥及使用方法 |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US20190224220A1 (en) | 2016-04-20 | 2019-07-25 | Abbvie Inc. | Carbidopa and L-Dopa Prodrugs and Methods of Use |
| WO2018059739A1 (en) | 2016-09-29 | 2018-04-05 | Berlirem Gmbh | L-dopa derivatives for the treatment of neurological diseases |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2015
- 2015-10-21 TW TW110101738A patent/TWI755257B/zh active
- 2015-10-21 WO PCT/US2015/056686 patent/WO2016065019A1/en not_active Ceased
- 2015-10-21 RS RS20190854A patent/RS58972B1/sr unknown
- 2015-10-21 CN CN201580069519.8A patent/CN107206013A/zh active Pending
- 2015-10-21 CN CN202010250046.4A patent/CN111454290B/zh active Active
- 2015-10-21 KR KR1020247023761A patent/KR20240113982A/ko active Pending
- 2015-10-21 CA CA2965379A patent/CA2965379A1/en not_active Abandoned
- 2015-10-21 ES ES15791424T patent/ES2739536T3/es active Active
- 2015-10-21 TW TW104134601A patent/TWI718999B/zh active
- 2015-10-21 KR KR1020177013734A patent/KR102537018B1/ko active Active
- 2015-10-21 SI SI201530761T patent/SI3209302T1/sl unknown
- 2015-10-21 MY MYPI2017701367A patent/MY189519A/en unknown
- 2015-10-21 AR ARP150103412A patent/AR102389A1/es unknown
- 2015-10-21 SM SM20190376T patent/SMT201900376T1/it unknown
- 2015-10-21 SG SG11201703170RA patent/SG11201703170RA/en unknown
- 2015-10-21 RU RU2017117413A patent/RU2743347C2/ru active
- 2015-10-21 LT LTEP15791424.3T patent/LT3209302T/lt unknown
- 2015-10-21 JP JP2017521517A patent/JP6567049B2/ja active Active
- 2015-10-21 EP EP19164151.3A patent/EP3569587A1/en not_active Withdrawn
- 2015-10-21 TR TR2019/08296T patent/TR201908296T4/tr unknown
- 2015-10-21 EP EP15791424.3A patent/EP3209302B1/en active Active
- 2015-10-21 CN CN202010123543.8A patent/CN111362980B/zh active Active
- 2015-10-21 HU HUE15791424 patent/HUE044115T2/hu unknown
- 2015-10-21 AU AU2015335941A patent/AU2015335941B2/en active Active
- 2015-10-21 MX MX2021003840A patent/MX393568B/es unknown
- 2015-10-21 UA UAA201704815A patent/UA120437C2/uk unknown
- 2015-10-21 KR KR1020237015051A patent/KR20230066484A/ko not_active Ceased
- 2015-10-21 DK DK15791424.3T patent/DK3209302T3/da active
- 2015-10-21 PL PL15791424T patent/PL3209302T3/pl unknown
- 2015-10-21 CN CN202010250040.7A patent/CN111494395B/zh active Active
- 2015-10-21 EP EP22204022.2A patent/EP4186510A1/en active Pending
- 2015-10-21 HR HRP20191285TT patent/HRP20191285T1/hr unknown
- 2015-10-21 RU RU2021103000A patent/RU2021103000A/ru unknown
- 2015-10-21 BR BR112017008198-9A patent/BR112017008198B1/pt active IP Right Grant
- 2015-10-21 MX MX2017005236A patent/MX381069B/es unknown
- 2015-10-21 PT PT15791424T patent/PT3209302T/pt unknown
- 2015-10-21 US US14/919,418 patent/US9446059B2/en active Active
-
2016
- 2016-07-21 US US15/216,009 patent/US20160362431A1/en not_active Abandoned
-
2017
- 2017-04-19 ZA ZA2017/02760A patent/ZA201702760B/en unknown
- 2017-04-20 SA SA521421115A patent/SA521421115B1/ar unknown
- 2017-04-20 IL IL251829A patent/IL251829B/en active IP Right Grant
- 2017-04-21 PH PH12017500746A patent/PH12017500746B1/en unknown
- 2017-09-26 US US15/715,245 patent/US10174061B2/en active Active
-
2018
- 2018-12-05 US US16/210,996 patent/US10730895B2/en active Active
-
2019
- 2019-07-19 CY CY20191100771T patent/CY1121826T1/el unknown
- 2019-07-30 JP JP2019139442A patent/JP6750076B2/ja active Active
- 2019-08-23 IL IL268885A patent/IL268885B/en active IP Right Grant
-
2020
- 2020-05-04 US US16/866,400 patent/US11091507B2/en not_active Expired - Fee Related
- 2020-08-04 IL IL276493A patent/IL276493A/en unknown
- 2020-08-11 JP JP2020135560A patent/JP6932227B2/ja active Active
-
2021
- 2021-03-04 AU AU2021201414A patent/AU2021201414B2/en active Active
- 2021-07-16 US US17/378,321 patent/US20220153765A1/en not_active Abandoned
- 2021-08-16 JP JP2021132161A patent/JP2021183628A/ja active Pending
-
2022
- 2022-10-24 US US17/971,836 patent/US20230106081A1/en not_active Abandoned
-
2023
- 2023-02-20 HU HUS2300009C patent/HUS2300009I1/hu unknown
- 2023-03-07 CY CY2023010C patent/CY2023010I1/el unknown
- 2023-03-20 NO NO2023013C patent/NO2023013I1/no unknown
- 2023-03-24 NL NL301224C patent/NL301224I2/nl unknown
- 2023-03-31 FI FIC20230014C patent/FIC20230014I1/fi unknown
- 2023-04-03 LU LU00304C patent/LUC00304I2/fr unknown
- 2023-06-08 LT LTPA2023519C patent/LTC3209302I2/lt unknown
- 2023-08-04 AU AU2023210650A patent/AU2023210650A1/en not_active Abandoned
- 2023-09-29 FR FR23C1035C patent/FR23C1035I2/fr active Active
- 2023-10-06 JP JP2023174083A patent/JP7688087B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084629A patent/JP2025118978A/ja active Pending
- 2025-09-25 AU AU2025238004A patent/AU2025238004A1/en active Pending